WuXi AppTec A.I CyberSecurity Scoring
28/03/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for WuXi AppTec in 2026.
No incidents recorded for WuXi AppTec in 2026.
No incidents recorded for WuXi AppTec in 2026.
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With over 41,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of 450 million patients annually. With the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. User information & community guidelines: https://www.fresenius-kabi.com/social-media-terms-conditions Imprint: www.fresenius-kabi.com/imprint
Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use
Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
Latest updates, reports, and threat intel affecting the global network.
A firm led by billionaire Li Ge, the chairman and CEO of research and clinical trial company Wuxi Apptec, sold a waterfront mansion in Fort Lauderdale for $12....
On January 17, 2025, WuXi AppTec, a leading global provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology,...
Earlier this week, efforts to reduce U.S. reliance on biotechnology companies in China stalled when the BIOSECURE Act (“BIOSECURE” or the...
After the House of Representatives passed the Biosecure Act last week, US biotechs could be forced to cut ties with five Chinese contract partners.
Chinese biotechnology firms including BGI, MGI as well as WuXi AppTec on Tuesday refuted the wrong allegations in a US bill passed by the US...
WuXi AppTec is pushing back on calls from members of Congress for the Pentagon to consider adding the company and its subsidiaries to the Department of Defense...
Delve into the ongoing controversy involving the Chinese company WuXi AppTec and the possible impact on U.S. national security measures.
US lawmakers are raising alarms about what they see as America's failure to compete with China in biotechnology, warning of the risks to US national security...
The company had previously been named in a bill introduced late last month that aims to bar federal contracts with some Chinese biotech...
OpenSIPS is a Session Initiation Protocol (SIP) server implementation. In versions prior to 3.6.6 and 4.0.0-rc1, the construct_uri() function concatenates multiple URI components (protocol, username, domain, port, params) into a fixed 1024-byte global BSS buffer without any bounds checking. When a routing script calls construct_uri() with an attacker-controlled username, a combined component length exceeding 1024 bytes overflows the buffer, corrupting adjacent global data with attacker-controlled content. The overflow reaches disable_503_translation, a global flag controlling SIP 503 response handling, allowing an attacker to deterministically set the flag via the URI username and alter the server's routing behavior for subsequent messages. Because the same buffer is shared with contact_builder(), the overflow also corrupts that function's data, and without a memory sanitizer the adjacent globals are silently overwritten on every request containing a long username. This issue has been fixed in versions 3.6.6 and 4.0.0-rc1.
A security vulnerability has been detected in RackTables up to 0.22.0/e5fff9f8aab339798ed47e8c6d7d977ed97a82bd. This vulnerability affects unknown code. The manipulation leads to cross-site request forgery. The attack is possible to be carried out remotely. The exploit has been disclosed publicly and may be used. The project maintainer confirms: "[I]t seems plausible, in that RackTables does not at this time have any CSRF prevention. You may assign a CVE ID to this, but there is no guarantee it will be handled in urgent, or even timely, manner, or at all."
A weakness has been identified in Ehco1996 django-sspanel up to 2023.12.26. This affects the function TicketDetailView of the file apps/sspanel/views.py of the component Support Ticket Handler. Executing a manipulation can lead to authorization bypass. The attack can be executed remotely. The vendor was contacted early about this disclosure but did not respond in any way. This vulnerability only affects products that are no longer supported by the maintainer.
Odysseus before commit 87babb5 contains a server-side request forgery vulnerability that allows admin-privileged attackers to direct the server to probe internal network resources by supplying arbitrary URLs to the embedding endpoint configuration without scheme, host, IP range, or DNS rebind validation. Attackers can submit loopback addresses, RFC 1918 ranges, or link-local addresses through the embedding endpoint API to partially read responses from cloud instance metadata services, internal APIs, and other hosts reachable from the server.
Odysseus before commit bf325f6 contains a missing authorization vulnerability that allows authenticated non-admin users to manage server-wide embedding backend configuration by invoking endpoint management routes that verify session authentication but omit the admin authorization guard. Attackers can supply an attacker-controlled URL to overwrite the embedding backend persisted in the endpoint configuration file and process environment, causing all subsequent embedding operations including chat messages, RAG queries, memory entries, and vault text to be transmitted in plaintext to the attacker-controlled destination, or delete the endpoint configuration to deny embedding service to all users.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.